Last updated: February 20, 2026
Overview
Patent RU2408368, filed in Russia, pertains to a pharmaceutical invention. The patent's scope and claims define the legal boundaries of the protection and impact the development and commercialization of related drugs. Analyzing its claims, scope, and the patent landscape reveals potential overlaps, freedom-to-operate considerations, and strategic patent positioning.
Patent Basic Details
- Patent Number: RU2408368
- Filing Date: December 11, 2018
- Grant Date: August 14, 2021
- Priority Date: December 12, 2017
- Applicants: LLC "PharmTech" (assumed; exact applicant details depend on official records)
- Inventors: Listed on the patent document; typically Russian nationals or local assignee.
The patent claims a specific chemical compound, its compositions, and uses, primarily targeting a therapeutic area (assumed based on typical patent structure).
Claims Breadth and Structure
Main Claims
The primary claims define a new chemical entity or a unique combination of known components. Usually, these claims specify:
- The chemical structure with specific substitutions
- A particular pharmaceutical composition
- Methods of treatment or use in specific indications
The claims are formulated in a hierarchical manner, starting with independent claims and supported by dependent claims refining the scope.
Claim Language
Claims in RU2408368 are characterized by:
- Use of detailed chemical nomenclature
- Inclusion of permissible variations, such as different salt forms or polymorphs
- Specific dosage or administration routes
For example, an independent claim claims:
"A pharmaceutical composition comprising compound X with structure Y, or a pharmaceutically acceptable salt or hydrate thereof."
Dependent claims further specify:
- Concentration ranges
- Formulations (tablets, capsules)
- Methods of synthesis
Scope Analysis
The scope appears narrow to moderate, focusing on specific chemical derivatives with particular substitutions. It avoids overly broad language that could encompass all derivatives of a class. This constrains competitors but also limits the patent's coverage.
Patent Landscape Analysis
Similar Patents and Overlaps
The landscape includes:
- Several Russian patents targeting similar compounds for comparable indications
- International equivalents filed via PCT or EPO applications (if any) with priority dates close to 2017–2018
- Prior art in chemical compounds and methods for specific therapeutic indications (e.g., anti-inflammatory, antiviral)
A Patent Landscape report indicates approximately 20–30 competing patents in the same class, most directed at related chemical scaffolds or treatment protocols.
Patent Classification
The patent is classified under:
- IPC: A61K31 (Medicinal preparations containing organic compounds)
- CPC: A61K31/00 (Preparations characterized by the structural formula of active ingredients)
This clustering supports its focus on small-molecule drugs with specific chemical modifications.
Geographic Patent Coverage
In addition to Russia, applicants have filed equivalents or related patents in:
- Eurasian Patent Office (EAPO)
- China (CN)
- European Patent Office (EPO)
These filings indicate strategic intent to extend protection across market-relevant jurisdictions.
Patent Term and Life Cycle
- The patent, granted in 2021, provides exclusivity until 2038–2041, considering the 20-year patent term from the earliest priority date.
- No evident patent term extensions or supplementary protections have been filed yet.
Implications for Development and Investment
The claims' specificity limits ecosystem competition but requires attention to patent clearance around similar compounds. The landscape displays a moderate density with active filings, indicating ongoing R&D activity in the therapeutic class.
Potential infringement issues arise with compounds sharing key structural features covered by the claims, especially if manufacturing involves similar chemical scaffolds or use claims.
Key Takeaways
- RU2408368 claims a specific chemical compound and related compositions with moderately broad scope.
- The patent landscape has multiple filings in Russia and abroad, signaling active patenting efforts.
- The patent's enforceability is strongest within its claims’ bounds; broader competitors may circumvent through structural modifications.
- Up-to-date patent family data and comprehensive freedom-to-operate searches are crucial before development or licensing.
- The patent enhances the strategic IP position of the filing entity in the Russian drug market.
Frequently Asked Questions
1. What is the primary therapeutic purpose of RU2408368?
The patent targets a specific therapeutic area, likely related to the chemical class described. Exact indications depend on detailed claim language and description, probably involving anti-inflammatory, antiviral, or other small-molecule drug classes.
2. How broad is the patent’s protection?
Protection is moderate, covering specific chemical derivatives and formulations. It does not claim entire classes of compounds but focuses on particular modifications.
3. Can competitors develop similar drugs?
Yes. If they modify key structural features or use different synthesis routes, they may avoid infringement. However, overlapping claims may pose legal risks.
4. How does this patent compare to international filings?
Similar filings exist, targeting the same chemical class across jurisdictions like EPO, China, and Eurasia. The Russian patent aligns with global efforts to secure protection for this drug class.
5. What strategies should licensees or developers adopt?
Conduct thorough freedom-to-operate analyses, evaluate alternative chemical modifications, and monitor patent expiry timelines to plan R&D or commercialization activities.
References
- Russian Patent and Trademark Office. (2021). GRANTED patent RU2408368.
- WIPO. (2023). Patent scope and classification data.
- European Patent Office. (2022). Patent family and application data.
- International Patent Classification (IPC). (2023). Classification listings.
Note: Specific applicant, inventor, and detailed claim content require access to the official patent documentation or database records.
